Biotechnology

Gilead Sciences Inc. (NYSE: GILD) is scheduled to report second quarter 2019 earnings results on Tuesday, July 30, after market…

AbbVie's (NYSE: ABBV) earnings and revenue for the second quarter of 2019 surpassed Wall Street's estimates. AbbVie reported adjusted EPS…

Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also…

AstraZeneca Plc (NYSE: AZN) topped market estimates for revenue and earnings in the second quarter of 2019, giving shares a…

AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the…

Bristol-Myers Squibb (NYSE: BMY) will be releasing its quarterly results amid growing skepticism over the planned acquisition of rival drugmaker…

Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% growth for its second-quarter earnings, helped by an increase in revenues. The results…

Advaxis Inc. (NASDAQ: ADXS) stock plunged to a record low of $1.54 on Tuesday as the late-stage biotech company has…

When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most…

Advaxis (NASDAQ: ADXS) reported that Q2 revenue decreased to $1.2 million from $1.7 million in the prior year quarter. The…

Immunogen Inc (IMGN) Q1 2019 earnings call dated May 03, 2019 Corporate Participants: Sarah Kiely -- Director of Investor Relations Mark Enyedy -- President and Chief…

Exelixis Inc. (NASDAQ: EXEL) surpassed Q1 earnings and revenue projections. The company reported earnings of $0.27 per share on revenue…

Novavax Inc (NASDAQ: NVAX) is slated to report its first quarter 2019 earnings results after market closes on Thursday. Novavax…

Biotechnology firm Amgen (Nasdaq: AMGN) reported first-quarter earnings that increased from last year and exceeded estimates, while revenues remained unchanged. Meanwhile,…

Fennec Pharmaceuticals Inc. (FENC) stock plunged to an all-time low of $4.69 on Tuesday. Investors were concerned about the future…

After getting halted in Nasdaq for sometime, shares of Aldeyra Therapeutics (ALDX) resumed trading and climbed up about 60% during…

Cesca Therapeutics (KOOL) Monday reported a wider net loss for fiscal 2018 when revenues of the biotechnology firm declined sharply.…

Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the…

Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after…

Exelixis (EXEL) reported Q4 earnings of 37 cents per share and revenue of $228.6 million that beat analysts' views. Analysts…

In the current environment, investment in the biotech stocks could be a risky recommendation for the investors. Despite its erratic…